Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study

Bruce E. Sands, Wolfgang Miehsler, William J. Tremaine, Paul J. Rutgeerts, Stephen B. Hanauer, Lloyd Mayer, Stephan R. Targan, Daniel K. Podolsky

Research output: Contribution to journalArticle

359 Scopus citations

Abstract

We report the experience of 11 patients (of 60 planned patients) enrolled in a double-blind, placebo-controlled clinical trial of infliximab in patients with severe, active steroid-refractory ulcerative colitis. The study was terminated prematurely because of slow enrollment. Patients having active disease for at least 2 weeks and receiving at least 5 days of intravenous corticosteroids were eligible to receive a single intravenous infusion of infliximab at 5, 10, or 20 mg/kg body weight. The primary endpoint used in this study was treatment failure at 2 weeks after infusion. Treatment failure was defined as 1) unachieved clinical response as defined by a modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death. Safety evaluations included physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences. Four of 8 patients (50%) who received infliximab were considered treatment successes at 2 weeks, compared with none of 3 patients who received placebo. Improvement in erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6 correlated with the clinical response observed in patients receiving infliximab. Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)83-88
Number of pages6
JournalInflammatory bowel diseases
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2001

Keywords

  • Infliximab
  • Monoclonal antibody
  • Steroid-refractory
  • Tumor necrosis factor alpha
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Fingerprint Dive into the research topics of 'Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study'. Together they form a unique fingerprint.

  • Cite this

    Sands, B. E., Miehsler, W., Tremaine, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001). Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflammatory bowel diseases, 7(2), 83-88. https://doi.org/10.1097/00054725-200105000-00001